Product Overview

Vaccinia Virus Capping Enzyme is a recombinant enzyme produced through Escherichia coli (E. coli) expression and is designed for efficient enzymatic capping of mRNA during in vitro transcription (IVT) workflows. It catalyzes the attachment of the 7-methylguanosine (m⁷G) cap structure to the 5′ end of mRNA, generating capped mRNA molecules that mimic naturally processed eukaryotic mRNA.

The 5′ cap structure plays a critical role in enhancing mRNA stability, reducing innate immune activation, and promoting efficient ribosome recognition for translation initiation. This product provides a reliable solution for mRNA vaccine development, gene therapy research, and GMP-scale mRNA manufacturing.

Manufactured under a GMP-compliant production environment, this product features an animal origin-free process, strict impurity control, and consistent batch-to-batch performance to meet the quality requirements of both preclinical research and commercial-scale production.

Key Features

GMP-Grade Manufacturing

• Produced under GMP-compliant conditions with a completely animal origin-free manufacturing process

• Free of β-lactam antibiotics

• Supported by DMF filing and comprehensive quality control documentation

• Ensures high batch-to-batch consistency for research and manufacturing applications

High Capping Efficiency

• Achieves >95% capping efficiency for standard mRNA sequences

• Enables efficient generation of capped mRNA with improved translation performance

Low Residual Impurities

• Nuclease-free formulation

• Strict control of residual impurities, including:

• Host cell DNA (HCD)

• Host cell proteins (HCP)

• Microbial contamination

• Metal ions

• Endotoxin

Compatible with Pre-Denaturation-Free Capping Workflow

• Supports capping reactions without mandatory pre-denaturation steps

• Simplifies workflow operation and improves process efficiency for large-scale mRNA production

No Patent Restrictions

• Suitable for flexible development and manufacturing applications without additional patent licensing concerns

Applications

Vaccinia Virus Capping Enzyme is widely used for enzymatic mRNA capping in nucleic acid drug development and manufacturing workflows, including:

mRNA vaccine development

Supports production of capped mRNA molecules with enhanced stability and translation activity.

Gene therapy applications

Enables preparation of high-quality capped mRNA for therapeutic research and development.

In vitro transcription (IVT) workflows

Provides an efficient enzymatic capping solution for mRNA synthesis processes.

GMP-scale mRNA manufacturing

Suitable for preclinical research, process development, and large-scale production of mRNA-based therapeutics.

Performance Data

High and Consistent Capping Efficiency

Vaccinia Virus Capping Enzyme demonstrates excellent mRNA capping performance across different mRNA templates, delivering consistently high capping efficiency compared with competing products.

• Capping efficiency >95% for standard mRNA sequences

• Maintains stable capping performance across different template types

• Supports production of high-quality capped mRNA for downstream applications

Pre-Denaturation-Free Capping Capability

The enzyme provides comparable capping efficiency with or without 65°C pre-denaturation treatment, enabling a simplified workflow.

• Eliminates the need for additional mRNA denaturation steps

• Reduces operational complexity

• Facilitates streamlined production processes for large-scale manufacturing

FAQ

Q1: What is Vaccinia Virus Capping Enzyme used for?

Vaccinia Virus Capping Enzyme is used for enzymatic addition of the 5′ mRNA cap structure during IVT workflows. It helps improve mRNA stability, reduce immunogenicity, and enhance translation efficiency.

Q2: What capping efficiency can this product achieve?

The product achieves more than 95% capping efficiency for standard mRNA sequences, providing reliable performance for mRNA research and manufacturing applications.

Q3: Is this product suitable for GMP manufacturing?

Yes. The product is manufactured under GMP-compliant conditions with animal origin-free processing, strict quality control, and DMF filing support, making it suitable for GMP-scale mRNA production workflows.

Q4: Does the capping reaction require mRNA pre-denaturation?

No. The product supports a pre-denaturation-free capping workflow, allowing simplified operation while maintaining high capping efficiency.

Q5: How should Vaccinia Virus Capping Enzyme be stored and transported?

The product should be transported under 0°C conditions and stored at -25°C to -15°C to maintain enzyme activity and product stability.

Related Products